scholarly journals Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipients

2018 ◽  
Vol 20 (2) ◽  
pp. e12855 ◽  
Author(s):  
E.R. Dubberke ◽  
K.A. Reske ◽  
M.A. Olsen ◽  
K. Bommarito ◽  
A.A. Cleveland ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Lung Transplant ◽  
Hematopoietic Cell ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

Epidemiology, risk factors, and outcome of Clostridium difficile infection in heart and heart-lung transplant recipients

2017 ◽  
Vol 31 (6) ◽  
pp. e12968 ◽  
Author(s):  
Jackrapong Bruminhent ◽  
Kelly A. Cawcutt ◽  
Charat Thongprayoon ◽  
Tanya M. Petterson ◽  
Walter K. Kremers ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Lung Transplant ◽  
Transplant Recipients ◽  
Heart Lung Transplant ◽  
Lung Transplant Recipients

Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus

2013 ◽  
Vol 184 (1) ◽  
pp. 599-604 ◽  
Author(s):  
Janet T. Lee ◽  
Bryan A. Whitson ◽  
Rosemary F. Kelly ◽  
Jonathan D'Cunha ◽  
Jordan M. Dunitz ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Lung Transplant ◽  
Calcineurin Inhibitors ◽  
Transplant Recipients ◽  
Adult Lung ◽  
Lung Transplant Recipients

Clostridium difficile infection increases mortality risk in lung transplant recipients

2013 ◽  
Vol 32 (10) ◽  
pp. 1020-1026 ◽  
Author(s):  
Janet T. Lee ◽  
Rosemary F. Kelly ◽  
Marshall I. Hertz ◽  
Jordan M. Dunitz ◽  
Sara J. Shumway
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Mortality Risk ◽  
Lung Transplant ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

scholarly journals 445Epidemiology and Outcomes of Clostridium difficile Infections in Heart and Heart-lung Transplant Recipients

2014 ◽  
Vol 1 (suppl_1) ◽  
pp. S168-S169
Author(s):  
Jackrapong Bruminhent ◽  
Charat Thongprayoon ◽  
Kelly Cawcutt ◽  
Raymund R. Razonable
Keyword(s):  
Clostridium Difficile ◽  
Lung Transplant ◽  
Transplant Recipients ◽  
Heart Lung Transplant ◽  
Lung Transplant Recipients

scholarly journals 2673. Risk Factors for Clostridium difficile Infection in Lung Transplant Patients

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S938-S938
Author(s):  
Joseph L DeRose ◽  
Peter Axelrod ◽  
Rafik Samuel ◽  
Heather Clauss
Keyword(s):  
United States ◽  
Risk Factors ◽  
Clostridium Difficile ◽  
Lung Transplantation ◽  
Clostridium Difficile Infection ◽  
Lung Transplant ◽  
The United States ◽  
Transplant Recipients ◽  
Transplant Patients ◽  
Lung Transplants

Abstract Background Clostridium difficile infection is a serious and common illness affecting almost 500,000 people in the United States each year. Solid-organ transplant recipients are at increased risk for this infection, with lung transplant patients being at the highest risk. Temple University Hospital (TUH) in Philadelphia has performed the most lung transplants in the United States over the last 2 years. Methods A retrospective case–control study was performed to identify patients diagnosed with C. difficile following lung transplantation at our institution between January 1, 2014 and April 30, 2018 (N = 35). We randomly selected control patients (N = 35) who had lung transplantation performed during this time but did not develop C. difficile infection. The study objectives were to characterize risk factors that are associated with C. difficile infection in lung transplant recipients and compare clinical outcomes in recipients with and without C. difficile. Statistical analysis was performed using Epi Info (CDC, Atlanta GA). Results The average age was 62.4 years, 64.7% were male, 75% were white and 69.1% of transplants were performed for underlying idiopathic pulmonary fibrosis. 52.9% of patients had “non-severe” C. difficile infection as defined by the 2018 Infectious Disease Society of America guidelines. Patients with C. difficile infection were more likely to have been treated for cytomegalovirus (CMV) viremia (OR 8.2, 95% CI 2.4–28.2, P = 0.0006) and were more likely to have received third- to fifth-generation cephalosporins (OR 4.0, 95% CI 1.4–11.2, P = 0.01) and/or carbapenems (OR 3.7, 95% CI 1.4–9.9, P = 0.02). Patients with C. difficile infection were more likely to experience multiple hospitalizations when compared with C. difficile-negative patients (3.6 vs. 8.4, P = 0.003). 22 of the 68 evaluable patients died during the study period, 9 of whom had C. difficile infection (P = NS). Conclusion Patients who received lung transplants and developed C. difficile infection were more likely to be treated for CMV viremia, receive antibiotics including cephalosporins and/or carbapenems and require repeat hospitalizations when compared with control patients who did not develop C. difficile infection following transplant. Disclosures All authors: No reported disclosures.

Sign in / Sign up

Export Citation Format

Share Document